MacroGenics | MGNX - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 645M 69M 2026-03
Amgen USD 95.64B 94.98B 2026-06
AstraZeneca USD 340M 144M 2026-06
Biogen USD 72.6M 12.6M 2025-06
Bristol-Myers Squibb USD 407M 4M 2026-06
Daiichi Sankyo JPY 3.57B 1.4B 2026-03
Eli Lilly USD 114.7M 134.3M 2025-09
Genmab DKK 139M 129M 2026-06
Geron USD 7.15M 150K 2026-03
Gilead Sciences USD 247M 7M 2026-06
J&J USD 43M 25M 2026-03
Karyopharm Therapeutics USD 12.55M 66K 2026-03
MacroGenics USD 4.89M 1.55M 2026-03
Merck USD 525M 46M 2026-06
Pfizer USD 667M 4M 2026-06
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
Xencor USD 7.35M 2.65M 2026-06